Leerink analyst Joseph Schwartz cut his price target for AMAG Pharmaceuticals to $45 after his survey of 31 obstetricians and gynecologists showed a "surprising willingness" to use generic Delalutin. Schwartz previously thought physicians would not be willing to accept the legal risk in pregnant women when using a generic. He believes, however, that AMAG's current valuation reflects this generic risk while ignoring the potential for the company to improve intramuscular Makena's formulation and acquire additional accretive assets. Schwartz keeps an Outperform rating on AMAG despite the target cut.